PULM - Pulmatrix Inc

PULM - Pulmatrix Inc

https://www.pulmatrix.com

Recent News

Powered by Alpha Vantage

Pulmatrix ( PULM ) Q2 Revenue Falls 100%

Motley Fool • 1 month, 1 week ago • score: 0.02

Pulmatrix ( NASDAQ:PULM ) , a biotechnology company known for its dry powder inhalation delivery platform iSPERSE™, released its second quarter results on August 6, 2025, covering the quarter that ended June 30, 2025. Pulmatrix reported zero revenue for the period ended June 30, 2025.

Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain - Pulmatrix ( NASDAQ:PULM )

Benzinga • 7 months, 3 weeks ago • score: 0.23

SAN DIEGO, Jan. 22, 2025 ( GLOBE NEWSWIRE ) -- Cullgen Inc. ( "Cullgen" ) , a privately-held, clinical-stage biopharmaceutical company applying its proprietary targeted protein degradation uSMITE™ platform to discover and advance therapeutics for the treatment of cancer and other diseases, today ...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ROIC, BERY, PULM on Behalf of Shareholders - Pulmatrix ( NASDAQ:PULM ) , Berry Global Gr ( NYSE:BERY )

Benzinga • 9 months, 2 weeks ago

NEW YORK, Nov. 26, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Retail Opportunity Investments Corp.

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Pulmatrix, Inc. - PULM

Benzinga • 10 months ago • score: 0.24

NEW YORK, Nov. 14, 2024 ( GLOBE NEWSWIRE ) -- Monteverde & Associates PC ( the "M&A Class Action Firm" ) , has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Pulmatrix, Inc., a clinical-stage biopharmaceutical company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company is headquartered in Lexington, Massachusetts.

52W High

$10.40

52W Low

$1.78

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.57

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

1.57

EV/Revenue (<3 favorable)

22.40

P/S (TTM) (<3 favorable)

48.20

P/B (<3 favorable)

3.17

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

0.66%

Institutions (25–75% balanced)

9.34%

Shares Outstanding

3,652,300

Float

3,628,100

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

369,000

Gross Profit (TTM)

-484,000

EPS (TTM)

-2.17

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-21.69%

ROE (TTM) (>15% strong)

-0.84%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-1.00

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—